Advanced search×
×

Oncotarget

Electronic ISSN
1949-2553

  1. Adhesion glycoprotein CD44 functions as an upstream regulator of a network connecting ERK, AKT and Hippo-YAP pathways in cancer progression.

    Oncotarget 6(5):2951 (2015) PMID 25605020

    We describe a novel crosstalk among ERK, AKT and Hippo-YAP pathways, with CD44 as an upstream regulator. High cell density leads to activation of ERK and AKT but inactivation of YAP in cancer cells. CD44 modulates cell proliferation and cell cycle but not apoptosis. The expression and activity of ce...
  2. Two hits are better than one: synergistic anticancer activity of α-helical peptides and doxorubicin/epirubicin.

    Oncotarget 6(3):1769 (2015) PMID 25593197

    We delineated the mechanism of this synergy by studying the apoptosis pathway and morphologic changes in the HeLa cell membrane. The mechanism of the HPRP-A1/DOX combination was found to involve enhanced apoptosis, which seemed to be caspase-dependent and involved both the extrinsic and intrinsic pa...
  3. RNA interference screening identifies a novel role for PCTK1/CDK16 in medulloblastoma with c-Myc amplification.

    Oncotarget 6(1):116 (2015) PMID 25402633

    We used kinome-wide RNA interference screening to identify novel kinases that may be targeted to inhibit the proliferation of c-Myc-overexpressing MB. The RNAi screen identified a set of 5 genes that could be targeted to selectively impair the proliferation of c-Myc-overexpressing MB cell lines: AKA...
  4. MED1 mediates androgen receptor splice variant induced gene expression in the absence of ligand.

    Oncotarget 6(1):288 (2015) PMID 25481872

    We performed protein co-immunoprecipitation, chromatin immunoprecipitation, and cell proliferation assays and found that MED1 is necessary for ARv567es induced UBE2C up-regulation and subsequent prostate cancer cell growth. Furthermore, p-MED1 is bound to ARv567es independent of full-length AR; p-ME...
  5. Irinotecan treatment and senescence failure promote the emergence of more transformed and invasive cells that depend on anti-apoptotic Mcl-1...

    Oncotarget 6(1):409 (2015) PMID 25565667

    We analyzed cell escape in response to irinotecan, a first line treatment used in colorectal cancer that induced senescence. We detected subpopulations of cells that adapted to chemotherapy and resumed proliferation. Survival led to the emergence of more transformed cells that induced tumor formatio...
  6. DNA replication stress as an Achilles' heel of cancer.

    Oncotarget 6(1):1 (2015) PMID 25595910

  7. Hypoxia-inducible factor 1 alpha is regulated by RBM38, a RNA-binding protein and a p53 family target, via mRNA translation.

    Oncotarget 6(1):305 (2015) PMID 25622105

    We showed that RNA-binding protein RBM38, a target of the p53 family, regulates HIF1α expression via mRNA translation. Specifically, we showed that under a hypoxic condition, ectopic expression of RBM38 decreased, whereas knockdown of RBM38 increased, the level of HIF1α protein. We also showed that...
  8. Classification of current anticancer immunotherapies.

    Oncotarget 5(24):12472 (2014) PMID 25537519 PMCID PMC4350348

    We propose a critical, integrated classification of anticancer immunotherapies and discuss the clinical relevance of these approaches....
  9. Ferroxitosis: a cell death from modulation of oxidative phosphorylation and PKM2-dependent glycolysis in melanoma.

    Oncotarget 5(24):12694 (2014) PMID 25587028 PMCID PMC4350353

    We term ferroxitosis. The redox cycling agent menadione causes a robust increase in oxygen consumption, accompanied by significant loss of intracellular ATP and rapid cell death. Conversely, either hypoxic adaptation or iron chelation prevents menadione-induced ferroxitosis. Ectopic expression of K2...
  10. Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia.

    Oncotarget 5(23):12371 (2014) PMID 25365263 PMCID PMC4323011

    We report characterization of possible roles of MELK in acute myeloid leukemia (AML). MELK is expressed in AML cell lines and AML blasts with higher levels in less differentiated cells. MELK is frequently upregulated in AML with complex karyotypes and is associated with worse clinical outcome. MELK...